secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcadia Biosciences, Inc. (RKDA)
CIK:        0001469443
Form:       8-K
Filed at:   2023-07-20T23:59:59+00:00
Accession:  0000950170-23-033652
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcadia begins strategic review, reports $18.8M cash and Q2 revenue guidance of $1.3-1.5M
--------------------------------------------------------------------------------

- Strategic review initiated; Lake Street Capital Markets as advisor; options include sale, merger, or other transactions.
- Cash and cash equivalents of $18.8M as of June 30, 2023; Q2 revenue expected between $1.3M and $1.5M.
- Exiting ProVault and SoulSpring body care brands, saving $3-4M annually starting August 2023.
- Expanded GoodWheat portfolio with launch of pancake mixes; Q2 results to be announced August 10, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1469443/000095017023033652/0000950170-23-033652-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1469443/000095017023033652/rkda-20230720.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-033652

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer